Myotonic Dystrophy Type 1 (Steinert Syndrome).
A rare genetic disease that progressively affects muscle function and other organs. Knowing its symptoms and treatment options is key to improving quality of life. Learn more about this condition and ongoing research.
Learn moreScientific information.
Specific information for health professionals.
Discovery of Natural Xanthines as active molecules in models of Myotonic Dystrophy, presented at the International Congress on Myotonic Dystrophy IDMC-11
See morePatent granted in USA 2017 and licensed to Myogem “CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2”
See moreMyogem receives the Seal of Excellence
See morePatent granted in USA 2019 and licensed to Myogem “COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY”
See moreMyogem participates in the “Summer School” Spanish Edition of the European program “Eurordis”
See morePresentation of MyoDM Preclinical Results at the International Congress on Myotonic Dystrophy IDMC-12
See moreRecognition with Seals of Excellence and Granting of the European R&D Project of the SME-1 program, to carry out the MyoDM clinical trials
See moreMyogem Initiates Clinical Study of MyoDM in Myotonic Dystrophy Type 1 (DM1)
See moreMyogem’s MyoDM clinical study successfully completes patient recruitment. Post on LinkedIn
See moreScientific article compiling the most recent drug development projects currently in the preclinical and clinical phases
See moreDoctoral thesis
See moreScientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation.
See moreKnow us better.
At Myogem Health Company, we work with passion, science, and innovation to improve the quality of life of people living with Steinert's Myotonic Dystrophy.
Discover who we are, our team, and the values that guide us.
ContactDiscover who we are, our team, and the values that guide us.
MyoDM, a breakthrough in the treatment of Steinert's Myotonic Dystrophy. Research and innovation at the service of your well-being.
Buy nowNews.
Scientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation.
View report
See moreDoctoral thesis
Highest qualification awarded by the Thesis Committee: Dr. Rafael Mañez Mendiluce**, Dr. Carmen Escolano Mirón***, Arturo López Castel****
See moreScientific article compiling the most recent drug development projects currently in the preclinical and clinical phases
View report
See more¿Do you have any questions
or need more information?
Fill out the form and our team will respond as soon as possible.